| 开始投产。 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | (二)募投项目先期投入及置换情况 | | | | | | | | | 本公司不存在募投项目先期投入及置换情况。 | | | | | | | | | (三)用闲置募集资金暂时补充流动资金情况 | | | | | | | | | 未发生使用闲置募集资金暂时补充流动资金的情况。 | | | | | | | | | (四) 对闲置募集资金进行现金管理，投资相关产品情况 | | | | | | | | | 公司分别于 2021 年 4 月 16 日、2021 年 5 月 | 12 日召开第三届董事会第二十 | | | | | | | | 七次会议和 2020 年年度股东大会，审议通过了《关于使用闲置募集资金进行现 | | | | | | | | | 金管理的议案》，同意在确保不影响募集资金投资项目建设和募集资金使用的情 | | | | | | | | | 50,000 万元的 况下，公司（包括控股子公司）使用单日最高余额不超过人民币 | | | | | | | | | ...

证券代码：603538 证券简称：美诺华 公告编号：2025-093 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告 〔2025〕10 号）、《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》以及《上海证券交易所上市公司自律监管指南第 1 号——公告格式》的相关 规定，现将宁波美诺华药业股份有限公司（以下简称"公司"或"本公司"）2025 年半年度的募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许[2020]2377 号）核准，公司向社会公开发 行 可 转 换 公 司 债 券 520 万 张 ， 每 张 面 值 100 元 ， 发 行 总 额 为 人 民 币 为人民币 512,697,629.67 元。该募集资金已于 2021 年 ...

Core Viewpoint - Luant Pharmaceutical (600789.SH) has received approval from the Shanghai Stock Exchange for its application to issue shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1] Fundraising Details - The total amount to be raised from the issuance is not exceeding 120 million yuan, which will be allocated to projects including high-end formulation intelligent manufacturing workshop, bio-pesticide base construction, new drug research and development, and working capital [1][2] - The total investment for the projects is approximately 128.42 million yuan, with specific allocations as follows: - High-end formulation intelligent manufacturing workshop: 44.24 million yuan - Bio-pesticide base construction: 43.22 million yuan - New drug research and development: 20.97 million yuan - Working capital: 20 million yuan [2] Issuance Participants - The issuance will involve no more than 35 qualified investors, including Hualu Group, which plans to subscribe for 23.81% of the shares issued, amounting to no more than 64,201,417 shares [3] - Other potential investors include securities investment fund management companies, securities firms, financial companies, asset management companies, insurance institutions, trust companies, and qualified foreign institutional investors [2] Shareholding Structure - As of September 30, 2024, the total share capital of the company is 898,669,632 shares, with Hualu Group holding 20.69% and Hualu Investment holding 3.13% [5] - Post-issuance, Hualu Group's shareholding will remain unchanged, ensuring that the control of the company does not change [5] Regulatory Compliance - The issuance is subject to compliance with relevant laws and regulations, and the company will fulfill its information disclosure obligations as required [1][4]

Group 1: Investment Trends in Guangdong - Private investment is a significant indicator of development expectations and confidence in Guangdong's economy [1] - The province is implementing policies to stimulate private investment, focusing on new demand creation and industry expectations [1][2] - There is a notable increase in investment in sectors like chips and robotics, with private capital actively seeking opportunities [2] Group 2: Market Dynamics - The private investment growth rate in Guangdong showed fluctuations in the first half of the year, reflecting a cautious approach from private real estate companies [1][2] - New consumption sectors have seen a rise in financing events, indicating a shift towards health foods, pet consumption, and smart living [3] - The real estate sector is adapting to new regulations, with increased transaction volumes in specific housing types, suggesting strong demand for upgrades [3][4] Group 3: Policy Support and Economic Outlook - Central government meetings have emphasized urban renewal and consumption, which are expected to drive a positive cycle of investment and consumption [3][4] - Guangdong has introduced 26 measures to deepen investment and financing reforms, targeting key sectors like railways and advanced manufacturing [6] - The province has recommended 104 key private investment projects with a total planned investment of 215.8 billion yuan [6] Group 4: Mergers and Acquisitions Activity - There is a surge in mergers and acquisitions in Guangdong, with 41 completed transactions in the first half of the year, amounting to 37.594 billion yuan [7][8] - Companies like Songfa Co. and TCL Technology are leveraging acquisitions to diversify and strengthen their market positions [7] - The provincial government is actively supporting the M&A market through various initiatives, enhancing the capital market's role in the economy [8]

Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]